HC Wainwright Lowers Mural Oncology (NASDAQ:MURA) Price Target to $6.00

Mural Oncology (NASDAQ:MURA) had its price target reduced by equities researchers at HC Wainwright from $18.00 to $6.00 in a note issued to investors on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price target suggests a potential upside of 344.44% from the company’s current price.

Several other research analysts have also recently weighed in on the stock. Jones Trading reiterated a “hold” rating on shares of Mural Oncology in a research note on Tuesday. Raymond James downgraded Mural Oncology from a “strong-buy” rating to an “outperform” rating and set a $18.00 target price on the stock. in a research report on Tuesday. Finally, Morgan Stanley lowered Mural Oncology from an “overweight” rating to an “equal weight” rating in a report on Tuesday. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $13.00.

Mural Oncology Stock Performance

Shares of NASDAQ:MURA opened at $1.35 on Wednesday. The stock’s 50-day simple moving average is $3.77 and its two-hundred day simple moving average is $3.58. The stock has a market capitalization of $23.26 million, a price-to-earnings ratio of -0.15 and a beta of 3.66. Mural Oncology has a 52-week low of $1.28 and a 52-week high of $5.12.

Mural Oncology (NASDAQ:MURA) last posted its quarterly earnings data on Tuesday, March 11th. The company reported ($2.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.96) by ($0.05). During the same period in the prior year, the firm earned ($3.57) EPS. As a group, equities analysts forecast that Mural Oncology will post -7.54 earnings per share for the current fiscal year.

Institutional Trading of Mural Oncology

Several institutional investors and hedge funds have recently modified their holdings of MURA. Commerce Bank bought a new position in Mural Oncology in the 3rd quarter worth $39,000. FMR LLC lifted its position in shares of Mural Oncology by 124.7% in the third quarter. FMR LLC now owns 20,580 shares of the company’s stock valued at $64,000 after acquiring an additional 11,423 shares in the last quarter. Point72 Asset Management L.P. bought a new position in shares of Mural Oncology in the third quarter worth about $340,000. Geode Capital Management LLC grew its position in shares of Mural Oncology by 2.6% during the third quarter. Geode Capital Management LLC now owns 190,056 shares of the company’s stock worth $595,000 after purchasing an additional 4,731 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in shares of Mural Oncology during the fourth quarter worth about $181,000. 80.21% of the stock is currently owned by institutional investors.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.